Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new
generation of biologic immunotherapy to treat cancers and Chemotherapy Induced Peripheral
Neuropathy (CIPN). The lead drug candidate, BXQ-350 modulates lysosomal sphingolipid metabolism
(S1P), inducing tumor cell death and imparting both innate and adaptive immune activity. BXQ-350 is a
first-in-class biologic containing the multifunctional, lysosomal activator protein, Saposin C in a nanovesicle formulation to treat cancers and potentially Chemotherapy Induced Peripheral Neuropathy (CIPN).
generation of biologic immunotherapy to treat cancers and Chemotherapy Induced Peripheral
Neuropathy (CIPN). The lead drug candidate, BXQ-350 modulates lysosomal sphingolipid metabolism
(S1P), inducing tumor cell death and imparting both innate and adaptive immune activity. BXQ-350 is a
first-in-class biologic containing the multifunctional, lysosomal activator protein, Saposin C in a nanovesicle formulation to treat cancers and potentially Chemotherapy Induced Peripheral Neuropathy (CIPN).
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Kentucky
Company HQ Country:
United States
Year Founded:
2006
Main Therapeutic Focus:
Lead Product in Development:
BXQ-350
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
multiple
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
